Biotechnology

Bio Lab Naturals, Inc., a Delaware Corporation (BLAB: OTC) Announces Entry into a Lease/Purchase Agreement.

March 30, 2021 4:00 PM

DENVER, CO / ACCESSWIRE / March 30, 2021 / Bio Lab Naturals, Inc., a Delaware corporation, "BLAB" (OTCQB:BLAB), based in Denver, Colorado, desires to provide information to its investors and shareholders related to a Lease/Purchase Agreement dated March 24, 2021. On March 24, 2021, BLAB, through its subsidiary, Prime Time Live, Inc. ("PTL"), entered into a Lease/Purchase Agreement (the "Agreement") with an unrelated third party, whereby PTL...

Read more

Pieris Pharmaceuticals Reports Full-Year 2020 Financial Results and Provides Corporate Update

March 30, 2021 7:00 AM

Company To Host an Investor Conference Call on Tuesday, March 30, 2021 at 8:00 AM EDT Pieris achieves $13 million milestone from AstraZeneca for initiation of PRS-060/AZD1402 phase 2a study and AstraZeneca to purchase $10 million equity stake in Pieris common stock as part of an amended collaboration agreement $13 million equity investment by Seagen in Pieris, in addition to a clinical trial and supply agreement to evaluate cinrebafusp...

Read more

Health Canada Provides Positive Feedback on Tetra Bio-Pharma’s Application for ARDS-003 to be Studied in COVID-19 Patients at Risk of Developing Acute Respiratory Distress Syndrome

March 30, 2021 2:00 AM

Health Canada acknowledges that the preclinical safety data are robust and sufficient to file a Clinical Trial Application aimed at treating hospitalized COVID-19 patients at risk of developing ARDS ARDS is the leading cause of mortality in patients with COVID-19 and develops in 20-67% of critically ill patients diagnosed with COVID-19 There is currently no standard, approved treatment for ARDS rendering the indication a significant unmet...

Read more

ANGLE PLC Announces Global Launch of Clinical Services Laboratories

March 30, 2021 2:00 AM

Delivering on strategy to accelerate commercialisation of the Parsortix system and act as a demonstrator to support product deployment UK and US clinical laboratories now open and ready to provide CTC analysis services and discussions with pharmaceutical industry customers ongoing GUILDFORD, SURREY / ACCESSWIRE / March 30, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that it has...

Read more

Experion Holdings Reports Financial Results for the Fourth Quarter and Fiscal Year Ended November 30, 2020

March 29, 2021 4:15 PM

VANCOUVER, BC / ACCESSWIRE / March 29, 2021 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31), Canada's solution to craft cannabis supply and builder of premium cannabis brands including its sought after and popular brand Citizen Stash is pleased to report its fourth quarter and fiscal year end financial results for the period ended November 30, 2020. "The fiscal year ended November 30, 2020 was a...

Read more

Applied UV to Host Full Year 2020 Conference Call on March 31st

March 29, 2021 8:30 AM

MOUNT VERNON, NY / ACCESSWIRE / March 29, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that the Company will host an investor conference call and live webcast to discuss...

Read more

Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)

March 29, 2021 8:05 AM

- Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma (NHL) towards Investigational New Drug (IND) filing in the United States - Study will evaluate the XCART process of neoantigen identification and generation of tumor-specific CAR T candidates, in a real-world clinical setting FRAMINGHAM, MA / ACCESSWIRE / March 29, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"...

Read more

Tetra Bio-Pharma Initiates Additional Studies on Leading Drug Candidate ARDS-003

March 26, 2021 2:00 AM

Tetra Bio-Pharma and Targeted Pharmaceuticals enter into an agreement to further its collaboration and co-development activities to advance Antiviral Central Nervous System Program The addressable global market for central nervous system drugs is expected to grow to $163.05 billion in 2025 OTTAWA, ON / ACCESSWIRE / March 26, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical...

Read more

Medical Data Systems, Inc.: Using Machine Learning To Enhance Account Recovery For Over 500 Hospitals Despite Pandemic Restrictions

March 25, 2021 10:20 PM

VERO BEACH, FL / ACCESSWIRE / March 25, 2021 / Hospitals have battled enormous challenges during the 2020 pandemic. Behind the scenes of the pandemic response one company's specialized account recovery process has helped over 500 hospitals nationwide keep cash flow moving and patient's informed of the changes in healthcare. Saving many hospitals from having to cut jobs and turn away patients. Behind all this success was one man's...

Read more

Pieris Announces Amendment of Existing Immuno-oncology Multi-target Collaboration with Seagen, a Clinical Trial and Supply Agreement to Evaluate Cinrebafusp Alfa (PRS-343) in Combination with TUKYSA(R) (tucatinib) in Gastric Cancer, and Strategic Equity Investment by Seagen

March 25, 2021 8:00 AM

Seagen will supply Pieris with TUKYSA® to evaluate the drug in combination with cinrebafusp alfa (PRS-343) in gastric cancer Pieris' co-development option for one program from existing multi-target collaboration amended to US co-promotion option with increased royalties if exercised Seagen to purchase $13 million equity stake in Pieris common stock BOSTON, MA / ACCESSWIRE / March 25, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS),...

Read more

Molecular Partners Nominates Dominik Höchli, M.D., for Election to Its Board of Directors

March 25, 2021 2:00 AM

Pharmaceutical industry expert with extensive knowledge of R&D and commercialization ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 25, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the nomination of Dominik Höchli, M.D., to the Company's Board of Directors proposed for election at the 2021...

Read more

Boston Red Sox to Partner with Applied UV to Install Airocide(R) Air Quality System in Fenway Park and Jet Blue Park

March 24, 2021 8:30 AM

MOUNT VERNON, NY / ACCESSWIRE / March 24, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that it has partnered with the Boston Red Sox to install the Airocide® Air...

Read more

Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer

March 24, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / March 24, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that the Company has officially opened its Phase I trial to evaluate Pritumumab (PTB), the Company's lead Monoclonal Antibody (Mab) therapeutic...

Read more

Lexaria Technology Generates Positive Stability Testing for World-Class Ready-to-Drink CBD Beverages

March 24, 2021 7:00 AM

DehydraTECHTM CBD-Beverage Demonstrates 93.4% Potency One Year After Production Lexaria's Nanoemulsification Processing Technique Ensures Content Uniformity and Homogeneity of CBD Distribution Without Need for Physical Mixing KELOWNA, BC / ACCESSWIRE / March 24, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced positive results...

Read more

CORRECTION: Wuhan Launches Medspresso CBD Infused Whole Bean Roasted Coffee

March 23, 2021 2:25 PM

This press release replaces the press release disseminated March 23rd, 2021 at 12:15 PM ET. The press release was missing the fifth paragraph. The corrected press release is below: CAPE TOWN, SA / ACCESSWIRE / March 23, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce today that the Company...

Read more

Wuhan Launches Medspresso CBD Infused Whole Bean Roasted Coffee

March 23, 2021 12:15 PM

CAPE TOWN, SA / ACCESSWIRE / March 23, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) ("Wuhan'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce today that the Company is launching the MedspressoTM CBD infused whole-bean roasted coffee line. The new line is offered in both whole-bean and ground coffee formats. The CBD infused whole-bean line was made possible...

Read more

Stella Diagnostics to Present at the Benzinga Biotech Small Cap Conference

March 23, 2021 11:35 AM

SALT LAKE CITY, UT / ACCESSWIRE / March 23, 2021 / Stella Diagnostics, Inc. (OTC Markets:JMDP) ("Stella" or "The Company") announced today that the Company's Chief Executive Officer, Dr. Joe Abdo, will participate in the Benzinga Biotech Small Cap Conference to be held virtually March 24-25, 2021. Dr. Abdo will present a corporate update and participate in a live Q&A with registered attendees starting at 2:10 pm EDT on Wednesday, March 24,...

Read more

RE-TRANSMISSION: GeneCentric Therapeutics Announces New US Patent Granted for Molecular Characterization of Non-Squamous Non-Small Cell Lung Cancer

March 23, 2021 9:30 AM

Patent Provides Framework for Further Development of Novel Lung Cancer Molecular Diagnostic Tests DURHAM, NC / ACCESSWIRE / March 23, 2021 / GeneCentric Therapeutics, a company making precision medicine more precise, announced today the granting of Patent No. 10,934,595 by the United States Patent and Trademark Office (USPTO), protecting another one of its novel RNA-based lung cancer gene signatures. This new patent provides further...

Read more

Afecta Pharmaceuticals Announces Grant of U.S. Patent

March 23, 2021 9:00 AM

IRVINE, CA / ACCESSWIRE / March 23, 2021 / Afecta Pharmaceuticals, a company focused on developing drugs that modulate key pathways that drive disease processes associated with immune disorders, neurological dysfunction and cancers, announced that the United States Patent and Trademark Office has granted a patent on March 9, 2021 for a class of novel compounds that inhibit the CCL5/RANTES pathway. The patent, U.S. Patent No. 10,940,132,...

Read more

Movano Inc. Prices $42.5 Million Public Offering of Common Stock

March 23, 2021 8:00 AM

PLEASANTON, CA / ACCESSWIRE / March 23, 2021 / Today, Movano Inc. (NASDAQ:MOVE), a health technology company designing devices that empower individuals to optimize their health in order to prevent and better manage chronic diseases, announced the pricing of its initial public offering of 8,500,000 shares of its common stock at a public offering price of $5.00 per share. All of the shares are being offered by Movano Inc. In addition, Movano Inc....

Read more